106 related articles for article (PubMed ID: 17582973)
1. Experiences in treatment of multiple sclerosis with betaferon in federation of Bosnia and Herzegovina.
Mehmedika-Suljic E; Burza-Bosnjak E; Bera M; Hasovic M; Sinanovic O
Med Arh; 2007; 61(1):34-6. PubMed ID: 17582973
[TBL] [Abstract][Full Text] [Related]
2. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
3. [Betaferon in the treatment of multiple sclerosis: efficacy standards].
Totolian NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):63-6. PubMed ID: 16117152
[No Abstract] [Full Text] [Related]
4. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
5. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
6. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
7. [Multiple sclerosis in the year 2000: advances in the treatment with interferon beta-1b].
Cendrowski W
Neurol Neurochir Pol; 2001; 35(5):855-65. PubMed ID: 11873598
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Etemadifar M; Janghorbani M; Shaygannejad V
Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
[TBL] [Abstract][Full Text] [Related]
9. Interferon beta in multiple sclerosis: predicting response at an early stage.
Killestein J; Hartung HP
J Neurol Neurosurg Psychiatry; 2008 Jun; 79(6):616-7. PubMed ID: 18487553
[No Abstract] [Full Text] [Related]
10. [The role of interferon beta in the treatment of multiple sclerosis].
Seeldrayers P
Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
[TBL] [Abstract][Full Text] [Related]
11. Betaferon efficiency indicators in the treatment of relapsing remitting form of multiple sclerosis.
Suljic E; Sinanovic O; Kurtovic-Alajbegovic A; Klupka-Saric I
Med Arch; 2013; 67(3):178-80. PubMed ID: 23848037
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.
Antonetti F; Finocchiaro O; Mascia M; Terlizzese MG; Jaber A
J Interferon Cytokine Res; 2002 Dec; 22(12):1181-4. PubMed ID: 12581490
[TBL] [Abstract][Full Text] [Related]
13. [Results of a multicenter study of Rebif-22 mcg administration in Russia].
Zavalishin IA; Gusev EI; Iakhno NN; Skoromets AA; Boĭko AN; Demina TL; Burlutskiĭ A P ; Beĭn BN; Sholomov II; Pereserdova AV; Stoĭda NI; Zakharova MN; Adarcheva LS; Niiazbekova AS; Askarova LSh; Oleĭnikov VG; Rebrova OIu; Shmidt TE; Davydovskaia MV; Totolian NA; Beskhmel'nitsina IA; Bragina OV; Ponomareva GL; Durseneva OM; Voronchikhina SA; Volkova LI; Turova EL; Streknev AG
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):73-8. PubMed ID: 12938639
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis.
Deisenhammer F; Giovannoni G
Mult Scler; 2004 Dec; 10(6):713-4; author reply 715. PubMed ID: 15584500
[No Abstract] [Full Text] [Related]
15. Landmark papers in multiple sclerosis.
Cross AH
Neurology; 2001 Dec; 57(12 Suppl 5):S1-2. PubMed ID: 11902588
[No Abstract] [Full Text] [Related]
16. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Goodin DS
Neurology; 2006 Oct; 67(7):1313-4. PubMed ID: 17030783
[No Abstract] [Full Text] [Related]
17. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Durelli L; Barbero P; Clerico M;
Neurology; 2006 Dec; 67(12):2264; author reply 2264-5. PubMed ID: 17190964
[No Abstract] [Full Text] [Related]
18. Guideline for the use of beta-interferons in patients with multiple sclerosis--a South African proposal.
Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA)
S Afr Med J; 2004 Nov; 94(11):917-21. PubMed ID: 15587456
[TBL] [Abstract][Full Text] [Related]
19. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
20. Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.
Qu ZX; Pliskin N; Jensen MW; White D; Arnason BG
Arch Neurol; 2001 Jan; 58(1):87-90. PubMed ID: 11176940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
